Drugs / ZN-A-1041
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07329972 | Nov → Dec 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07051993 | Jun → Jul 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04487236 | Oct 2020 → Apr 2024 | HER2 positive breast carcinoma | Suzhou Zanrong Pharma Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05593094 | Sep 2020 → Aug 2027 expected | HER2 positive breast carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZN-A-1041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07051993 ↗ |
| Route | Oral | “Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle” NCT04487236 ↗ |